David Cohen, MD
Internal Medicine · Wynnewood, PANPI 1215908645
Payments from drug & device makers
Across 142 payments — averaging $98.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$11K
- Novo Nordisk$533
- Inspire Medical Systems, Inc.$413
- Pfizer$261
- Idorsia Pharmaceuticals US Inc$174
- AstraZeneca$159
- plus $1K from 21 others
What the payments were for
- Speaking & faculty fees$9,32067%
- Travel & lodging$1,0958%
- Food & beverage$3,50725%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 30 | $11,204 |
| Novo Nordisk | 31 | $533 |
| Inspire Medical Systems, Inc. | 6 | $413 |
| Pfizer | 11 | $261 |
| Idorsia Pharmaceuticals US Inc | 5 | $174 |
| AstraZeneca | 4 | $159 |
| Organogenesis Inc. | 1 | $131 |
| AbbVie | 6 | $117 |
| Esperion Therapeutics, Inc. | 2 | $116 |
| Amgen | 7 | $113 |
| E.r. Squibb & Sons, L.L.C. | 6 | $108 |
| Lilly USA, LLC | 5 | $86 |
| Boehringer Ingelheim | 3 | $78 |
| GSK | 5 | $75 |
| Bayer | 3 | $60 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| Dexcom, Inc. | 2 | $42 |
| Abbott | 2 | $40 |
| Daiichi Sankyo Inc. | 2 | $30 |
| Merck | 2 | $26 |
| Merz North America, Inc. | 1 | $25 |
| Philips North America LLC | 1 | $20 |
| Medtronic | 1 | $20 |
| Bausch Health US, LLC | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Almatica Pharma LLC | 1 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$10,658
- Inspire$356
- Puraply Antimicrobial$131
- NEXLIZET$101
- NEXLETOL$101
How this compares
$13,934 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 184 | $195,362 |
| OzempicSemaglutide | 164 | $181,425 |
| TrulicityDulaglutide | 129 | $148,857 |
| XareltoRivaroxaban | 100 | $99,564 |
| EliquisApixaban | 62 | $51,667 |
| MounjaroTirzepatide | 40 | $48,359 |
| JanuviaSitagliptin Phosphate | 29 | $34,228 |
| FarxigaDapagliflozin Propanediol | 15 | $15,493 |
| SymbicortBudesonide/Formoterol Fumarate | 43 | $11,631 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $10,175 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 43 | $7,535 |
| Atorvastatin Calcium | 559 | $7,005 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,422 |
| Valsartan | 155 | $5,387 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $4,906 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $86 | $197,216169 claims |
| Boehringer IngelheimJardiance | $78 | $195,362184 claims |
| Novo NordiskOzempic | $533 | $181,425164 claims |
| Johnson & JohnsonXarelto | $11,204 | $99,564100 claims |
| PfizerEliquis | $261 | $51,66762 claims |
| MerckJanuvia | $26 | $34,22829 claims |
| AstraZenecaFarxiga, Symbicort | $159 | $27,12458 claims |
| GSKAnoro Ellipta | $75 | $10,17522 claims |
| AbbVieSynthroid | $117 | $2,32327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Wynnewood
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.